ReviewFrontiers in immunology2018
Peptide Vaccines for Leishmaniasis.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Efficacy of vaccines based on chimeric or multiepitope antigens for protection against visceral leishmaniasis: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Leish-F1 Multi-epitope Lentiviral Vaccine as a Novel Candidate Against Leishmania major in Balb/c Mice.Biochemical genetics · 2026Article
- The critical role of artificial intelligence and bioinformatics in accelerating peptide-based vaccine discovery for tackling global infectious diseases.Briefings in bioinformatics · 2026Review
- Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide.Frontiers in immunology · 2026Article
- In vitro anti-Trypanosomatid activity and chemical profile of crude extracts of Chromolaena hookeriana and Campuloclinium macrocephalum (Asteraceae).Memorias do Instituto Oswaldo Cruz · 2026Article
- A Quantitative Polymerase Chain Reaction (qPCR) Protocol Predictive of Treatment Outcome in Cutaneous Leishmaniasis Caused byOpen forum infectious diseases · 2025Article
- Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis.Frontiers in immunology · 2025Article
- Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets againstFrontiers in immunology · 2025Article
- Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.Current drug discovery technologies · 2025Review
- Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.PloS one · 2025Article
- Multi-epitope vaccine design against leishmaniasis using IFN-γ inducing epitopes from immunodominant gp46 and gp63 proteins.Journal, genetic engineering & biotechnology · 2024Article
- Enhancing Control ofAnimals : an open access journal from MDPI · 2024Article
- Microbial ecology of sandflies-the correlation between nutrition,Frontiers in veterinary science · 2024Article
- Immunoinformatic Analysis ofRecent advances in inflammation & allergy drug discovery · 2024Article
- Recent Advances in Immunotherapy for Breast Cancer: A Review.Breast cancer (Dove Medical Press) · 2024Review
- From classical approaches to new developments in genetic engineering of live attenuated vaccine against cutaneous leishmaniasis: potential and immunization.Frontiers in public health · 2024Review
- Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis.Scientific reports · 2023Article
- PepAnalyzer: predicting peptide properties using its sequence.Amino acids · 2023Article
- Article
- Identification of Immunodominant Proteins of theVaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.